Abstract
The ubiquitin–proteasome pathway has an important role in regulating apoptosis and
the cell cycle. The function of proteasomes is mediated by three main catalytic activities:
(1) chymotrypsin-like (CT‐L), (2) trypsin-like (T‐L), and (3) peptidylglutamyl peptide
hydrolyzing (PGPH). Recently, proteasome inhibitors have been revealed to have an
antitumor effect, and have been used to treat cancers such as multiple myeloma. Previous
studies have reported that some flavonoids can inhibit proteasome activity in tumor
cells. To further investigate the proteasome-inhibitory mechanism of flavonoids, we
examined the effects of the plant flavonoids apigenin, chrysin, and luteolin on the
three individual catalytic activities in various cancer cell lines. Using fluorogenic
substrates specific for proteasome catalytic subunits, we demonstrated the subunit
specificity of each flavonoid. Addition of apigenin, chrysin and luteolin inhibited
CT‐L and T‐L catalytic activities in a dose-dependent manner, whereas their effect
on PGPH catalytic activity was weak. Our study suggested that these flavonoids have
a specific role in inhibition of CT‐L and T‐L proteasome catalytic activities.
Key words
flavonoids - proteasomes - inhibitors
References
- 1
Ciechanover A.
The ubiquitin-proteasome pathway: on protein death and cell life.
EMBO J.
1998;
17
7151-7160
- 2
Li B, Dou Q P.
Bax degradation by the ubiquitin-proteasome-dependent pathway: involvement in tumor
survival and progression.
Proc Natl Acad Sci USA.
2000;
97
3850-3855
- 3
Myung J, Kim K B, Crews C M.
The ubiquitin-proteasome pathway and proteasome inhibitors.
Med Res Rev.
2001;
21
245-273
- 4
Naujokat C, Hoffman S.
Role and function of the 26S proteasome in proliferation and apoptosis.
Lab Invest.
2002;
82
956-980
- 5
Groll M, Heinemeyer W, Jager S, Ullrich T, Bochtler M, Wolf D H, Huber R.
The catalytic sites of 20S proteasome and their role in subunit maturation: a mutational
and crystallographic study.
Proc Natl Acad Sci USA.
1999;
96
10976-10983
- 6
Ciechanover A, Orian A, Schwartz A L.
Ubiquitin-mediated proteolysis; biological reglation via destruction.
Bioessays.
2000;
22
442-451
- 7
Crawford L J, Walker B, Ovaa H, Chauhan D, Anderson K C, Morris T C, Irvine A F.
Comparative selectivity and specificity of the proteasome inhibitors bzlllcocho, ps-341,
and Mg-132.
Cancer Res.
2006;
66
6379-6386
- 8
Kazi A, Daniel K G, Smith D M, Kumar N B, Dou Q P.
Inhibition of the proteasome activity, a novel mechanism associated with the tumor
cell apoptosis-inducing ability of genistein.
Biochem Pharmacol.
2003;
66
965-976
- 9
Nam S, Smith D M, Dou Q P.
Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo.
J Biol Chem.
2001;
276
13322-13330
- 10
Ross J A, Kasum C M.
Dietary flavonoids: bioavailability, metabolic effects, and safety.
Annu Rev Nutr.
2002;
22
19-34
- 11
Feng X, Zhang L, Zhu H.
Comparative anticancer and antioxidant activities of different ingredients of Ginkgo biloba extract (ECB761).
Planta Med.
2009;
75
792-796
- 12
Seelinger G, Merfort I, Schempp C M.
Anti-oxidant, anti-inflammadtory and anti-allergic activities of luteolin.
Planta Med.
2008;
14
1667-1677
- 13
Neuhouser M L.
Dietary flavonoids and cancer risk: evidence from human population studies.
Nutr Cancer.
2004;
50
1-7
- 14
Chen D, Chen M S, Cui Q C, Yang H, Dou Q P.
Structure-proteasome-inhibitory activity relationships of dietary flavonoids in human
cancer cells.
Frontiers Biosci.
2007;
12
1935-1945
- 15
Chen D, Daniel K G, Chen M S, Kuhn D J, Landis-Piwowar K R, Dou Q P.
Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia
cells.
Biochem Pharmacol.
2005;
69
1421-1432
- 16
Landis-Piwowar K R, Milacic V, Chen D, Yang H, Zhao Y, Chan T H, Yan B, Dou Q P.
The proteasome as a potential target for novel anticancer drugs and chemosensitizers.
Drug Resist Updat.
2006;
9
263-273
- 17
Kane R C, Brose P F, Frarell A T, Pazdur R.
Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior
therapy.
Oncology.
2003;
8
508-513
- 18
Richardson P G, Barlogie B, Berenson J, Singhai S, Jagannath S, Irwin D, Rajkumar S V,
Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski R Z, Kuter D, Limentani S A,
Lee S, Hideshima T, Esseltine D L, Kauffman M, Adams J, Schenkein D P, Anderson K C.
A phase 2 study of bortezomib in relapsed, refractory myloma.
N Eng J Med.
2003;
348
2609-2617
Dr. Yi-Xin Wu
Department of Biochemistry
Hamamatsu University School of Medicine
1-20-1 Handa-yama
Higasi-ku
Hamamatsu
431-3192 Shizuoka
Japan
Phone: + 81 5 34 35 23 26
Fax: + 81 5 34 35 23 27
Email: yixinwu@hama-med.ac.jp